Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)-Reference-Cited by-同舟云学术

Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)

Published:2016-12-26 Issue:9 Volume:31 Page:1872-1881
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Patel V M,Balakrishnan K,Douglas M,Tibbitts T,Xu E Y,Kutok J L,Ayers M,Sarkar A,Guerrieri R,Wierda W G,O'Brien S,Jain N,Stern H M,Gandhi V

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu2016382.pdf

Reference65 articles.

1. Montserrat E, Moreno C . Chronic lymphocytic leukaemia: a short overview. Ann Oncol 2008; 19 (Suppl 7): vii320–vii325.

2. Chiorazzi N, Rai KR, Ferrarini M . Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–815.

3. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563–574.

4. Burger JA, Gribben JG . The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 2014; 24: 71–81.

5. Tomlinson MG, Woods DB, McMahon M, Wahl MI, Witte ON, Kurosaki T et al. A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells. BMC Immunol 2001; 2: 4.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mouse models of CLL: In vivo modeling of disease initiation, progression, and transformation;Seminars in Hematology;2024-06

2. Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia;Blood Advances;2024-01-12

3. Predictive Power of Machine Learning Models for Relapse Outcomes in Acute Myeloid Leukemia: Unveiling Key Genes and Pathways for Improved Patient Management;2023-12-07

4. The pathogenesis and development of targeted drugs in acute T lymphoblastic leukaemia;British Journal of Pharmacology;2023-02-09

5. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax;Clinical Cancer Research;2023-01-18